Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of September 2022, with the report dated September 27, 2022. The filing discloses the entry into material agreements regarding a private securities offering and associated voting arrangements.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial metric disclosed relates to the capital raise:
- Gross Proceeds: $2,194,827.30 from the sale of 1,625,798 ordinary shares.
- Purchase Price: $1.35 per share.
Material Changes and Transactions
The primary material event is the execution of a Securities Purchase Agreement (SPA) on September 22, 2022, with Zhijun Xiao, a non-affiliate non-U.S. person. Key terms include:
- Issuance: 1,625,798 ordinary shares at $1.35 per share.
- Conditions: Issuance is contingent upon Nasdaq's completion of its review for listing the shares.
- Regulation: The offering is exempt from registration under Regulation S of the Securities Act of 1933.
Outlook, Risks, and Contingencies
Voting Agreements: Concurrent with the SPA, the investor (Mr. Xiao) entered into voting agreements with existing shareholders Feng Zhou (approx. 2.941% voting power) and Hao Xia (approx. 7.47% voting power). Mr. Xiao irrevocably granted a power of attorney to these individuals for all voting rights, including director elections and corporate transaction approvals, for the maximum period permitted by law.
Contingencies: The closing of the share issuance is subject to the satisfaction of conditions, specifically the Nasdaq listing review.
Investor Verification Checklist
- Verify the completion of the Nasdaq listing review for the newly issued shares.
- Confirm the final closing date and actual issuance of the 1,625,798 shares.
- Review the full text of the Voting Agreements (Exhibits 4.1 and 4.2) to understand the duration and scope of the voting power transfer.
- Check subsequent filings for any updates on the company's liquidity position following this capital raise.